-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4191 Evaluating the Effectiveness and Security of Antifungal Prophylaxis in Acute Lymphoblastic Leukemia Induction ChemotherapyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Clinical Research, Diseases, Real-world evidence, Clinical procedures, Lymphoid Malignancies, Adverse Events, Technology and Procedures
Monday, December 9, 2024, 6:00 PM-8:00 PM

Yang Zhou1*, Hongsheng Zhou2,3* and Qifa Liu, MD4

1Southern Medical University, Guangzhou, China
2Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, China
3Department of Hematology, People's Hospital of Ganzhou, Ganzhou, China
4Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background and objectives: Patients suffering from hematologic malignancies face a high risk of developing invasive fungal disease (IFD). Primary antifungal prophylaxis (PAP) is a key strategy to reduce the incidence of IFD in patients with acute myeloid leukemia (AML), those receiving hematopoietic stem cell transplantation (HSCT), and those with myelodysplastic syndrome (MDS). Nonetheless, clinical data regarding PAP in ALL patients is scarce, owing to major drug interactions. This paper aims to evaluate the efficacy and safety of PAP in ALL patients through real-world research.

Methods: A retrospective cohort study was carried out at a single center, focusing on ALL patients aged over 14 who received their first induction chemotherapy at our hospital from January 2011 to January 2021. Our study excluded individuals with a background of IFD, those who declined treatment and were released from the hospital, and those whose cases were inaccessible. The identification of IFD adhered to the guidelines set by the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG).

Results: The study included 482 patients, 316 of whom undergoing PAP treatment. Of the 482 patients, 13 developed proven or probable IFD (2.7%), and 60 developed possible IFD. There was a notably reduced occurrence of IFD in the prevention group compared to the non-prevention group (36/316, 11.4% vs. 37/166, 22.3%, P = 0.002). The multifactorial Cox regression analysis revealed a notable decrease in IFD occurrences due to PAP (HR = 0.306, P < 0.001). The primary medications administered in PAP included caspofungin (n = 113), voriconazole (n = 99), and micafungin (n = 53). The caspofungin group exhibited no adverse drug reactions. Patients experiencing neutropenia for more than 10 days and those on corticosteroids for 7 days or more showed a reduced mortality risk in the PAP group compared to the nonprophylactic group (HR = 0.615, P = 0.021).

Conclusions: The practical research we conducted revealed that PAP independently safeguards against IFD in ALL patients undergoing induction therapy. Furthermore, caspofungin's safety record for treating PAP in ALL patients is positive.

Disclosures: No relevant conflicts of interest to declare.

See more of: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract
*signifies non-member of ASH